Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown
Aybintio Joins Amgen And Pfizer Avastin Rivals Ready For Expiry
Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.
You may also be interested in...
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.
With the European Commission’s approval of Aybintio (bevacizumab), Samsung Bioepis now has five approved biosimilars for Europe.
Second-quarter earnings results from two of the Big Three – Teva and Mylan – hold much of the intrigue in August, while more competition in the nascent Avastin biosimilar market could materialize in Europe.